NervGen Pharma Extends the Expiry Date of Certain Stock Options
NervGen Pharma Extends the Expiry Date of Certain Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 2, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced a two-year extension of the expiry date of certain stock options (the "Options") granted to a consultant of the Company on April 23, 2021 and July 16, 2021, such that the terms of the Options shall be extended from three (3) years to five (5) years following the original grant dates, respectively. All other terms of the Options, including the exercise price, remain the same.
溫哥華，不列顛哥倫比亞省-(Newsfile Corp.-2023年6月2日)-NervGen製藥公司(TSXV：NGEN)(OTCQX：NGENF)(“NervGen”或“公司”)，一家致力於開發治療神經系統損傷的創新解決方案的臨床期生物技術公司，宣佈將某些股票期權的到期日延長兩年。選項“)於二零二一年四月二十三日及二零二一年七月十六日授予本公司顧問，使購股權條款分別由原來授出日期起計三(3)年延展至五(5)年。所有其他購股權條款，包括行使價，均維持不變。
About NervGen
關於NervGen
NervGen is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The Company's initial target indications are spinal cord injury, Alzheimer's disease, and multiple sclerosis. For more information, go to .
NervGen是一家臨床階段的生物技術公司，致力於開發創新的治療方法，使神經系統在受損後能夠自我修復，無論是由於受傷還是疾病。該公司最初的目標適應症是脊髓損傷、阿爾茨海默病和多發性硬化症。有關更多資訊，請訪問。
For further information, please contact:
如需更多資訊，請聯繫：
Bill Adams, Chief Financial Officer
badams@nervgen.com
比爾·亞當斯，首席財務官
郵箱：baadams@nergen.com
Huitt Tracey, Corporate Communications
htracey@nervgen.com
604.537.2094
Huitt Tracey，企業傳播部
郵箱：htrey@nerggen.com
604.537.2094
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問